Alain C Mita

Alain C Mita

UNVERIFIED PROFILE

Are you Alain C Mita?   Register this Author

Register author
Alain C Mita

Alain C Mita

Publications by authors named "Alain C Mita"

Are you Alain C Mita?   Register this Author

51Publications

1711Reads

44Profile Views

Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?

Cancer 2020 Jan 19;126(1):58-66. Epub 2019 Sep 19.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32501DOI Listing
January 2020

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.

Invest New Drugs 2019 02 18;37(1):76-86. Epub 2018 Apr 18.

Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0602-0
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0602-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521838PMC
February 2019

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.

Oncotarget 2017 Oct 30;8(49):86769-86783. Epub 2017 Sep 30.

University of Arizona Cancer Center and Department of Medicine, Division of Translational and Regenerative Medicine, University of Arizona, Tucson, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689724PMC
October 2017

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

J Clin Oncol 2017 Jul 4;35(19):2117-2124. Epub 2017 Apr 4.

Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.6795
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.6795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493051PMC
July 2017

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 01 30;12(1):145-151. Epub 2016 Sep 30.

Birmingham Veterans Administration Hospital, Birmingham, Alabama; University of Alabama-Birmingham Comprehensive Cancer Center, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.09.131DOI Listing
January 2017

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

World J Methodol 2016 Mar 26;6(1):25-42. Epub 2016 Mar 26.

Jun Gong, Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5662/wjm.v6.i1.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804250PMC
March 2016

Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.

Mol Cancer Ther 2015 Jun 25;14(6):1404-13. Epub 2015 Mar 25.

Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-1036DOI Listing
June 2015

Pharmacokinetic study of aldoxorubicin in patients with solid tumors.

Invest New Drugs 2015 Apr 12;33(2):341-8. Epub 2014 Nov 12.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite MS31, Los Angeles, CA, 90048, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0183-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387275PMC
April 2015

Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.

Invest New Drugs 2014 Dec 13;32(6):1236-45. Epub 2014 Aug 13.

Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St. Louis, MO, 63110, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-014-0145-y
Publisher Site
http://dx.doi.org/10.1007/s10637-014-0145-yDOI Listing
December 2014

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Dec 11;74(6):1241-50. Epub 2014 Oct 11.

Institute for Drug Development, Cancer Therapy and Research Center (CTRC), University of Texas Health Science Center, San Antonio, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2602-xDOI Listing
December 2014

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.

Cancer Chemother Pharmacol 2014 Dec 12;74(6):1113-24. Epub 2014 Oct 12.

Institute for Drug Development, Cancer Therapy and Research Center at UTHSCSA, University of Texas Health Science Center San Antonio, 4th Floor, Zeller Building, 7979 Wurzbach Road, San Antonio, TX, 78229, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2572-zDOI Listing
December 2014

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 12;20(7):1900-9. Epub 2014 Feb 12.

Authors' Affiliations: Vall d'Hebron Institut d'Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain; University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; University of Leicester, Leicester, United Kingdom; University Hospital of Zürich, Zürich, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, New York; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1710DOI Listing
April 2014

Vascular-disrupting agents in oncology.

Expert Opin Investig Drugs 2013 Mar 15;22(3):317-28. Epub 2013 Jan 15.

Experimental Theraputics Program, Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, LA, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2013.759557DOI Listing
March 2013

Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?

Clin Cancer Res 2012 Dec 22;18(24):6574-9. Epub 2012 Oct 22.

Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-1584DOI Listing
December 2012

Heat shock proteins: a potential anticancer target.

Curr Drug Targets 2011 Dec;12(14):2001-8

Institute for Drug Development at CTRC, The University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829339DOI Listing
December 2011

The hedgehog knows many tricks.

Curr Drug Targets 2011 Dec;12(14):2091-5

Scottsdale Clinical Research Institute, Scottsdale, AZ 85238, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829429DOI Listing
December 2011

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

Target Oncol 2011 Jun 4;6(2):69-94. Epub 2011 May 4.

Department of Hematology Oncology, Institute for Drug development, The University of Texas Health Science Center San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-011-0178-5DOI Listing
June 2011

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

Cancer Chemother Pharmacol 2011 Apr 3;67(4):751-64. Epub 2010 Jun 3.

START (South Texas Accelerated Research Therapeutics), 4319 Medical Drive, Suite 205, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1372-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064895PMC
April 2011

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Clin Cancer Res 2010 Jan 22;16(1):141-53. Epub 2009 Dec 22.

Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas 78245, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1385DOI Listing
January 2010

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.

Clin Cancer Res 2008 Aug;14(16):5000-5

Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-0746DOI Listing
August 2008

Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.

Clin Cancer Res 2007 Jun;13(11):3293-301

Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2496DOI Listing
June 2007

Design, conduct, and interpretation of organ impairment studies in oncology patients.

J Clin Oncol 2006 Jul;24(21):3509-10; author reply 3510-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.06.6795DOI Listing
July 2006

Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.

Clin Colorectal Cancer 2004 Jul;4(2):107-23

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 4th floor Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/ccc.2004.n.014DOI Listing
July 2004